Target Price | $125.28 |
Price | $90.70 |
Potential |
38.12%
register free of charge
|
Number of Estimates | 18 |
18 Analysts have issued a price target Blueprint Medicines Corp. 2025 .
The average Blueprint Medicines Corp. target price is $125.28.
This is
38.12%
register free of charge
$167.00
84.12%
register free of charge
$81.00
10.69%
register free of charge
|
|
A rating was issued by 20 analysts: 14 Analysts recommend Blueprint Medicines Corp. to buy, 5 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2025 of
38.12%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 249.38 | 508.07 |
22.22% | 103.73% | |
EBITDA Margin | -190.32% | -34.72% |
24.95% | 81.76% | |
Net Margin | -212.96% | -12.06% |
26.76% | 94.34% |
18 Analysts have issued a sales forecast Blueprint Medicines Corp. 2024 . The average Blueprint Medicines Corp. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2024. The average Blueprint Medicines Corp. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2024. The average Blueprint Medicines Corp. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -8.37 | -0.97 |
10.48% | 88.41% | |
P/E | negative | |
EV/Sales | 11.34 |
17 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Blueprint Medicines Corp. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Blueprint Medicines Corp....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.